Promore Pharma has two programs in late-stage clinical development: Ensereptide (PXL01), aimed for prevention of post-surgical adhesions and dermal scarring, is currently being prepared for Phase III on patients undergoing flexor tendon repair surgery in the hand; and
Ropocamptide (LL-37), is being developed as a chronic leg ulcers treatment, where a Phase IIb trial (HEAL LL-37) is ongoing on patients with venous leg ulcers has just been finalized with promising results on wounds larger than 10 cm2.
The pharmaceutical candidates are therapeutic peptides that are derived from human sequences that are part of the innate immune system, having multiple biological functions and properties. Ensereptide and ropocamptide have proven efficacy from both non-clinical and clinical studies.